A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany rak jajnika lub rak endometrium (w grupie monoterapii)
- •Rozpoznany rak jajnika (w grupie terapii skojarzonej)
- •Zaawansowana lub rozsiana choroba nowotworowa
✗ Disqualifies
- •Przerzuty do mózgu niekontrolowane
- •Historia zapalenia opon mózgowych spowodowanego rakiem
- •Aktywna infekcja bakteryjna, wirusowa, grzybiczna lub pasożytnicza
- •Problemy z rogówką oka lub przeszczep rogówki
- •Poważne powikłania z poprzednich leczenia
- •Poważna choroba serca
- •Zaburzenia rytmu serca
- •Historia zapalenia płuc lub choroby śródmiąższu płuc
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (12)
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
Little Rock, United States
START - Los Angeles
Los Angeles, United States
SCRI - Florida Cancer Specialists
Sarasota, United States
St. Francis Medical Center (OSF Healthcare)
Peoria, United States
Karmanos Cancer Center
Detroit, United States
Start - Ny
Long Island City, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Atrium Health - Wake Forest
Charlotte, United States
Ohio State University Wexner Medical Center
Columbus, United States
SCRI - Sydney Kimmel Cancer Center - Jefferson Health
Philadelphia, United States
SCRI - Mary Crowley Cancer Research
Dallas, United States
START Mountain
Salt Lake City, United States
Trial contact
Clinical Trial Manager Lead
Central email mailbox - Whitehawk Therapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.